Generic Name and Formulations:
Chlorzoxazone 375mg, 750mg+; tabs; +scored.
Various generic manufacturers
Indications for Chlorzoxazone:
As adjunct to rest, physical therapy, and other measures in acute, painful musculoskeletal conditions.
375mg: 1 tab 3–4 times daily; may increase to 2 tabs (750mg) 3–4 times daily if inadequate response. 750mg: ⅓ tab (250mg) 3–4 times daily. Painful musculoskeletal conditions: initially ⅔ tab (500mg) 3–4 times daily; may increase to 1 tab (750mg) 3–4 times daily if inadequate response. May reduce dose based on improvement.
Known drug intolerance.
Monitor for hepatotoxicity; discontinue if hepatic dysfunction or abnormal liver enzymes develop. Known allergies or history of. Discontinue if sensitivity reaction occurs. Pregnancy.
Additive effects with concomitant alcohol, other CNS depressants.
Muscle relaxant (central).
Drowsiness, dizziness, lightheadedness, malaise, overstimulation; rare: skin rash, petechiae, ecchymosis, fatal hepatocellular toxicity.
Formerly known under the brand name Lorzone.
Endocrinology Advisor Articles
- Use of In-Hospital Continuous Subcutaneous Insulin Infusion: A Consensus Statement
- Better Control With DPP-4 Inhibitors vs NPH Insulin in Type 2 Diabetes
- Achieving Glycemic Control in T2D After Basal Insulin Initiation
- Osteoporosis Drug Shows Cardioprotective Potential at 10-Year Follow-Up
- Effects of the Two Types of Anorexia Nervosa on Bone Metabolism
- Diabetes Treatments
- Incretins, Thiazolidinediones Associated With Better Glycemic Control in T2D
- No Link Between HbA1c Levels and Wound Healing in Patients With Diabetic Foot Ulcers
- Risk for Fetal Loss Early in Pregnancy Not Greater With Noninsulin vs Insulin Therapy
- Risk for Iodine Deficiency and Hypothyroidism High in Children on Parenteral Nutrition
- Inverse Association Between Serum 25(OH)D Levels and Risk for Diabetes
- Glycemic Control Variations for Children, Adolescents With T1D in High-Income Countries
- Late-Life Mobility Limitations Linked to Obesity After Arthroplasty for OA in Women
- Fracture Risk Should Be Monitored in Bisphosphonate Drug Holiday
- Provider Counseling for Weight Loss Up for Arthritis, Overweight